Navigation Links
Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia
Date:11/5/2009

rly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that nearly 13,000 new cases of AML will be diagnosed and approximately 9,000 deaths from AML will occur in the U.S. in 2009. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

This press release contains forward-looking statements, including without limitation statements related to the potential efficacy and commercial potential of voreloxin and Sunesis' plans to launch a pivotal trial of voreloxin including the timing thereof. Words such as "believe," "potential," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectati
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
10. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
11. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ov.24/PRNewswire/-- ,, WHAT:RomHoubens,aBelgian...oaccident,wasactuallyfullyconsciousandawakeduringt...t.TheDynaVoxEyeMaxwasfeaturedinthesegmenttoillustr...scanunlockcommunication. ,, WHEN:GoodMorningAme....dynavoxtech.com ,, WHO:RomHoubenswasanengi...
(Date:11/24/2009)....24/PRNewswire-FirstCall/--AnadysPharmaceuticals,I...tthe21stAnnualPiperJaffrayHealthcareConferenceonTu...conferenceisbeingheldatTheNewYorkPalaceHotel.Steve...nadys,willprovideanoverviewofAnadysanditsclinicald...ratepresentationwillbesimultaneouslywebcastandcanb...
(Date:11/24/2009)....24/PRNewswire/--Accumetrics,Inc.,aprivately-heldd...irstrapidandeasy-to-usediagnosticsystemformeasurin...s(e.g.Plavix®andaspirin),announcedtodaythatTi...ryJ.Tibbitts,ChiefFinancialOfficerofAccumetrics,wi...erJaffrayHealthCareConferencebeingheldinNewYorkCit...
Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Dr Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show 13558 1Dr Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show 13558 2Dr Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show 13558 3IRIDEX Reports Second Quarter 2009 Financial Results 54491 1IRIDEX Reports Second Quarter 2009 Financial Results 54491 2IRIDEX Reports Second Quarter 2009 Financial Results 54491 3IRIDEX Reports Second Quarter 2009 Financial Results 54491 4IRIDEX Reports Second Quarter 2009 Financial Results 54491 5IRIDEX Reports Second Quarter 2009 Financial Results 54491 6Martek Signs Sole Source ARA Supply Agreement with Puleva Food S L 13557 1Martek Signs Sole Source ARA Supply Agreement with Puleva Food S L 13557 2Martek Signs Sole Source ARA Supply Agreement with Puleva Food S L 13557 3
...- Gentium S.p.A. (Nasdaq:,GENT) announced the pres...t support the safety, activity, synergy and potent...ion with anticancer,therapy in multiple myeloma. I...pany,s ongoing Phase I/II clinical trial for patie...ith Defibrotide in,combination with chemotherapy, ...
... - Cytochroma Inc.,announced today positive data f...The initial top-line results from this trial,showe...e study,results are expected in August 2007. , The...l,placebo-controlled, randomized study of CTA018 ...n this trial, the safety of,CTA018 Injection was e...
Other Medicine Technology:Gentium's Defibrotide Seen as Active in Multiple Myeloma 2Gentium's Defibrotide Seen as Active in Multiple Myeloma 3Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3
(Date:11/25/2009)...sks placed under the skin kill tumor cells, study ...News) -- A cancer vaccine delivered in a fingernai... a new study reports. , The method uses polymer...ed with tumor-specific antigens and implanted unde...k tumors. The Harvard University scientists who de...
(Date:11/25/2009)...HINGTON,Nov.25/PRNewswire-FirstCall/--TheAdvisoryB...participateinthe21stAnnualPiperJaffrayHealthCareCo...cember2,2009at3:00PM(EST),willbetheCompany,sChiefE...sChiefFinancialOfficer,MichaelT.Kirshbaum.Theprese...te,foundat http://www.advisoryboardcompany.com ,th...
(Date:11/25/2009)...NTURA,Fla.,Nov.25/PRNewswire/--DanielTouizer,CEOof...ranteedissuehealthinsurancebenefitprograms,isconce...bermeansnearlyoneinfiveAmericansarewithoutafull-ti...unemploymentratesaredeterminedbytheU-6number,which... Dani e l T ouizer ."Thesestatisticsarealarm...
(Date:11/25/2009)...ES (Nov. 25, 2009) Melvin R. Kaplan, MD, FACP, a ...research institute that became Los Angeles Biomedi...er (LA BioMed), will be honored by the American Co...he care of patients. , At its April 22, 2010 mee...s will present Dr. Kaplan with the Ralph O. Claypo...
(Date:11/25/2009)...hemo boosts surgery success for patients with live...Y, Nov. 25 (HealthDay News) -- Adding the drug cet...rs and boost the odds of successful surgery in col... liver lesions, new research suggests. , , Tum... half of patients with colorectal cancer. Most com...
Breaking Medicine News(10 mins):Health News:Cinergy Health Commentary on Health Care for the Unemployed 2Health News:1 of LA BioMed's founders to be honored 2Health News:Cetuximab Helps Treat Colorectal Cancer 2
...step forward in the field of AIDS was disclosed by...ording to this 2-5AN6B, a nucleic acid, could actu...rus from replicating. This work was led by Rob...d for AIDS treatment will be effective in treating...
...ersing brain impairment that strikes in the early ...been identified by scientists.// The findings...n form of BSE, if it can be detected before it has... infected. But many scientists believe that thousa...
... a U.S based company promises a test that will s...sts.// The company has come out with a proced...atal test that searches for chromosomal abnormalit...he market there is no test available that can reli...
...nment has refused to grant product patent for Gliv...arma giant. As a result Novartis may not be able t...gapore and China are the countries where Novartis ...sion by the Indian government could hamper the lau...
...ts of Pinewood elementary in Prince George, Canada...ken strips were served to them as part of the scho...a case of food poisoning was registered only after... immediately notified the Northern Health authorit...
...e mouth heal more slowly in women and older adults...cago reveals.// "While wounds to the skin heal...ested the opposite is true for healing of wounds i...uth wounds heal faster than women's." Older wo...
Other Medicine News:Health News:Researchers Make Strides in VCJD Detection 2Health News:Simple Blood Test may Replace Invasive Prenatal Tests 2Health News:Oral Wounds Heal Slower in Women, Older Adults 2
... Deeper Lesions ,Designed for the treatment ...Freezor MAX is a powerful ablation-only catheter. ...s designed to provide maximum cryo performance. It... cryocatheters, but its larger shaft and ablation ...
...is GEs premier digital cardiovascular system that ...raphy, and a new dimension of comfort and diagnost...tomer input, using Six Sigma practices, GE has cre...ar system that delivers what customers want: Bette...
...onitors and controls patient temperature primarily...ssociated with surgery, trauma, or other medical c... feedback provided from a patient temperature prob...bient (room air) and 42C (107.6F) to achieve a pre...
...onic Stethoscope Model 4100WS features amplificati...echnology allowing you to reduce ambient noise by ...ical body sounds. Three frequency modes are availa...ounds: Bell (20-200 Hz), Diaphragm (100-500 Hz), a...
Medicine Products: